The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...

Eli Lilly and Novo Nordisk continue to ramp production facilities and capacity for booming weight-loss drugs like Wegovy and Zepbound, with Lilly this week announcing a $3 billion investment to ...